Retina Yucatan1

29/10/2025

https://www.facebook.com/share/1BYMyvdwGL/?mibextid=wwXIfr

Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology....

20/10/2025

The PRIMA Visual Prosthetics.

The results are astounding and a major advance, say surgeons involved in international research using the pioneering technology.

03/10/2025

https://www.facebook.com/share/p/1BD1swjrs3/

04/06/2024

Retinosis pigmentaria tipo RPGR y microbiota. Estudios comienzan, si esta interesado contáctenos.

30/04/2024

¡
Análisis moleculares 600 dólares!

MejoraVisionMD.com

12/02/2024

https://www.facebook.com/share/7xfi8qkGzaQKJkjv/?mibextid=I6gGtw

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

05/02/2024

Tratamiento genico distrofias de retina conos>bastones, Stargardt tipo mutacional ABCA4
Ascidian Therapeutics announces first-ever IND for an RNA exon editor as FDA approves trial plan and fast tracks ACDN-01 in Stargardt Disease https://www.modernretina.com/view/ascidian-therapeutics-announces-first-ever-ind-for-an-rna-exon-editor-as-fda-approves-trial-plan-and-fast-tracks-acdn-01-in-stargardt-disease via @

According to the company, ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.

04/02/2024

Tratamiento para Stargardt y otras retinopatías ABCA4. ¡Contáctenos !

Investigators from Proqr Therapeutics NV have tested their product QR-1011, an antisense oligonucleotide designed to correct splicing abnormalities within the ABCA4 gene that affect protein expression levels, in Stargardt disease.

06/10/2023

Choroideremia

Its sights set on cancer and rare diseases, Boston- based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year hC Bio is among a small set of biotechs pioneering tRNAs as a new therapeutic modality to edit proteins and restore their function without the safety conc...